The earnings call highlighted BioNTech's strategic advancements and strong financial position, with significant partnerships and acquisitions enhancing their pipeline and capabilities. However, challenges remain, including a net loss, reduced COVID-19 vaccine uptake, and a missed trial endpoint in the melanoma study. While the company is making positive strides, the financial losses and COVID-19 challenges present notable hurdles.

Company Guidance -

Q3 2025

During BioNTech's second quarter 2025 earnings call, the company provided detailed guidance on its strategic priorities and financial performance. Revenues for the quarter reached approximately €261 million, a significant increase from €129 million in the same period in 2024, driven primarily by the COVID-19 vaccine collaboration. The company maintained a strong financial position with €16 billion in cash and security investments. BioNTech reaffirmed its 2025 financial guidance, anticipating revenues between €1.7 billion and €2.2 billion, with R&D expenses projected between €2.6 billion and €2.8 billion. The company is focusing on its oncology pipeline, particularly the BNT327 bispecific antibody and mRNA cancer immunotherapies, FixVac and iNeST, with multiple Phase II and III trials underway. The strategic collaboration with BMS is expected to bring in $1.5 billion in upfront payments and up to $7.6 billion in potential milestones. Additionally, BioNTech is preparing for the global rollout of a new COVID-19 vaccine variant, pending regulatory approvals, and is investing in mRNA technology through the acquisition of CureVac.

Increased Revenues

Total revenues for Q2 2025 reached approximately EUR 261 million, compared to EUR 129 million in the same period of 2024, mainly driven by higher revenues from the COVID-19 vaccine collaboration.

Strong Strategic Partnerships

BioNTech entered a global 50-50 co-development and co-commercialization collaboration with Bristol-Myers Squibb (BMS) to accelerate the clinical development of BNT327.

BNT327 Development and Progress

Initiated two global pivotal clinical trials in small cell and non-small cell lung cancer. The company plans to start a Phase III trial in triple-negative breast cancer later this year.

Robust Financial Position

BioNTech maintained a strong financial position with EUR 16 billion in cash plus security investments.

Strategic Acquisitions and Expansions

Completed the acquisition of Biotheus and announced a strategic transaction to acquire CureVac, enhancing mRNA capabilities.

Expansion in the UK

Expanded partnership with the UK government, planning to invest up to GBP 1 billion over the coming decade in regional R&D activities.

BioNTech SE (BNTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BNTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 03, 2025	2025 (Q3)	-1.17 / -	0.941	―	―	―
Aug 04, 2025	2025 (Q2)	-2.65 / -1.86	-3.904	52.38% (+2.05)
May 05, 2025	2025 (Q1)	-2.66 / -2.01	-1.522	-32.06% (-0.49)
Mar 10, 2025	2024 (Q4)	0.52 / 1.25	2.208	-43.16% (-0.95)
Nov 04, 2024	2024 (Q3)	-1.82 / 0.94	0.778	20.90% (+0.16)
Aug 05, 2024	2024 (Q2)	-2.38 / -3.90	-0.918	-325.32% (-2.99)
May 06, 2024	2024 (Q1)	-1.44 / -1.52	2.382	-163.90% (-3.90)
Mar 20, 2024	2023 (Q4)	2.76 / 2.21	10.76	-79.48% (-8.55)
Nov 06, 2023	2023 (Q3)	-0.69 / 0.78	8.11	-90.40% (-7.33)
Aug 07, 2023	2023 (Q2)	-0.97 / -0.92	7.495	-112.25% (-8.41)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BNTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$107.34	$110.03	+2.51%
May 05, 2025	$104.94	$101.10	-3.66%
Mar 10, 2025	$108.78	$105.35	-3.15%
Nov 04, 2024	$111.48	$108.97	-2.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.